To acquire Personal Genome Service, Total Health and Research Services business lines, and its Biobank and associated assets.

The previously announced ASTM D4169-22 and ISTA Package Distribution Testing Service expansions are now fully operational.

CellProthera will tech transfer to CELLforCURE by SEQENS this year, with plans to produce clinical batches starting in 2026.

Aims to provide cell therapy R&D with standardized MSC products, optimized culture media, and cryopreservation solutions.

Shift Bioscience (Shift), a biotech company using an AI-powered virtual cell to fight age-driven diseases, appointed Lord ...

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.

GC Biopharma has partnered with Körber to implement a large-scale Manufacturing Execution System (MES) project across ...

The new board will work with Abzena's scientific and commercial leadership to provide strategic guidance and insights.

Aptamer Group plc has announced two new development contracts for its Optimer binders and a licensing heads of terms ...

Genentech has announced plans to invest more than $700 million in a new 700,000 square foot drug manufacturing facility.

Ratio has entered into an agreement with Wasatch Group to partner and construct a radiopharmaceutical research and ...

BioMarin has entered into a definitive agreement to acquire Inozyme Pharma Inc. for a total consideration of approximately ...